For the Inventor, By the Inventor

Enter assignee name

Berkeley, CA, United States of America

Xoma Technology Ltd.

USPTO Granted Patents = 84

% Expired Patents = 25.0

CIPO Patents = 10

EPO Patents = 28

Forward Citations = 633

Loading Chart...

Loading Chart...

82 inventors (with patents filed for the assignee):

Arnold H Horwitz (22 out of 49 patents)

Linda Masat (17 out of 20 patents)

Marina Roell (13 out of 18 patents)

4. Daniel H Bedinger (11 out of 16 patents)

5. Amer M Mirza (11 out of 16 patents)

6. Mary Haak-Frendscho (10 out of 47 patents)

7. Roger G Little, Ii (10 out of 36 patents)

8. Gang Chen (10 out of 57 patents)

9. Toshihiko Takeuchi (8 out of 22 patents)

10. Patrick J Scannon (7 out of 30 patents)

11. Alan M Solinger (7 out of 10 patents)

12. Marc D Better (7 out of 29 patents)

13. Shireen S Khan (6 out of 9 patents)

14. Ajay J Narasimha (6 out of 6 patents)

15. Robert Bauer (6 out of 6 patents)

Core Competencies:

TGF-Beta Inhibitors

PD-1 Antibodies

Monoclonal Antibodies

Cancer Treatment

Immune Modulation

Antibody Production

Tumor Microenvironment

Biologics

Therapeutic Peptides

Antibody Fragments

Recombinant Proteins

Antimicrobial Agents

84 patents: Sort by Forward Citations

1. 12071475 - Antibodies that bind transforming growth factor beta (TGF beta) and methods of use thereof for treatment (2024-08-27),

2. 11685775 - Method of increasing the ratio of effector T cells to regulatory T cells in a tumor by administering to a subject a TGF-beta inhibitor and a PD-1 antibody (2023-06-27),

3. 11098111 - Method of treating cancer by administering an antibody that binds transforming growth factor beta (TGF-beta) 1, TGF-beta 2 and TGF-beta 3 (2021-08-24),

4. 11034759 - Humanized M-CSF specific monoclonal antibodies, kits, and uses thereof (2021-06-15),

5. 10683347 - Treatment of cancer using anti-TGF-β and anti-PD-1 antibodies (2020-06-16),

6. 10358486 - Nucleic acids encoding, and methods of producing, antibodies specific for transforming growth factor (TGF)-β (2019-07-23),

7. 10167334 - Treatment of cancer using anti-TGF-BETA and PD-1 antibodies (2019-01-01),

8. 9926371 - M-CSF specific monoclonal antibody and uses thereof (2018-03-27),

9. 9885711 - Screening methods (2018-02-06),

10. 9732143 - Methods and materials for enhancing functional protein expression in bacteria (2017-08-15),

11. 9714285 - TGF-beta-specific antibodies and methods of use thereof for treatment (2017-07-25),

12. 9541004 - Antagonist antibodies against EphB3 (2017-01-10),

13. 9522186 - M-CSF specific monoclonal antibody and uses therof (2016-12-20),

14. 9145458 - Antibodies specific for TGF-β and methods of treatment thereof (2015-09-29),

15. 9102711 - Methods and materials for targeted mutagenesis (2015-08-11),

Xoma Technology Ltd., based in Berkeley, CA, specializes in the development of innovative cancer immunotherapy solutions. The company focuses on advanced therapeutic modalities, including TGF-Beta inhibitors and PD-1 antibodies, to enhance immune modulation and improve cancer treatment outcomes. With expertise in monoclonal antibody production and a deep understanding of the tumor microenvironment, Xoma is dedicated to creating biologics that address unmet medical needs in oncology.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

84 Patents

#6 in Berkeley, CA

#1,021 in California

#4,425 in US

#9,048 in the World

Berkeley, CA, United States of America

Xoma Technology Ltd.

Forward Citations = 633

82 inventors:

Arnold H Horwitz (22 out of 49 patents)

Linda Masat (17 out of 20 patents)

Marina Roell (13 out of 18 patents)

4. Daniel H Bedinger (11 out of 16 patents)

5. Amer M Mirza (11 out of 16 patents)

Please report any incorrect information to [email protected]

Loading…